Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Researchers examined the predictive and prognostic value of ¹⁸F-FES PET/CT for patients treated with endocrine therapy plus CDK4/6 inhibitors. Data from 127 patients with recurrent/metastatic ER+ HER2- breast cancer suggested that ER expression determined by ¹⁸F-FES PET/CT predicted the efficacy of CDK4/6 inhibitor–based endocrine therapy and correlated with survival outcomes.